EPO revokes Monsanto melon patent

The European Patent Office (EPO) has revoked Monsanto’s patent covering virus-resistant melons on technical grounds, following opposition to its registration by the Indian government and activist group No Patents on Seeds.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

13 July 2026 The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.

Biotech

Merck KGaA agrees $11.3bn deal in major life sciences expansion

26 June 2026 Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.

Biotech

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

25 June 2026 Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.

More features

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

IP Federation elects Philips licensing leader as new president

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

UPC upholds injunction in Invisalign maker’s software dispute with rival

BioNTech and Pfizer secure big European win over mRNA patent

Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin

EPO revokes Monsanto melon patent

More on this story

Editor's picks

Editor's picks

More features